Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;11(3):269-76, 4p following 269.
doi: 10.1593/neo.81396.

Early stage diagnosis of oral cancer using 1H NMR-based metabolomics

Stefano Tiziani  1 , Victor Lopes, Ulrich L Günther
Affiliations
Free PMC article

Early stage diagnosis of oral cancer using 1H NMR-based metabolomics

Stefano Tiziani et al. Neoplasia. 2009 Mar.
Free PMC article

Abstract

Oral cancer is the eighth most common cancer worldwide and represents a significant disease burden. If detected at an early stage, survival from oral cancer is better than 90% at 5 years, whereas late stage disease survival is only 30%. Therefore, there is an obvious clinical utility for novel metabolic markers that help to diagnose oral cancer at an early stage and to monitor treatment response. In the current study, blood samples of oral cancer patients were analyzed using nuclear magnetic resonance spectroscopy to derive a metabolic signature for oral cancer. Using multivariate chemometric analysis, we obtained an excellent discrimination between serum samples from cancer patients and from a control group and could also discriminate between different stages of disease. The metabolic profile obtained for oral cancer is significant, even for early stage disease and relatively small tumors. This suggests a systemic metabolic response to cancer, which bears great potential for early diagnosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Superimposition of two representative 1H NMR spectra (projections of JRES spectra), which show the average signals from the serum samples of healthy subjects (blue line) and patients with disease (red line) after application of a generalized log transformation. Predominant metabolite resonances are labeled on the spectrum. Ala indicates alanine; Gluc, glucose; Lac, lactate; Val, valine.
Figure 2
Figure 2
Principal components analysis scores plot of 1H NMR spectra of human blood sera from OSCC patients (●) and from healthy controls (▼).
Figure 3
Figure 3
PLS-DA scores plot of 1H NMR spectra of human blood sera using two classes: OSCC patients (● early and ■ late stage diseases) and healthy controls (▼).
Figure 4
Figure 4
Loadings plots for the first principal component for different regions of the spectrum. A representative NMR spectrum of human serum from an OSCC patient is shown above the loadings plots. Signals representing the most relevant discriminatory metabolites of healthy individuals (positive loadings) and OSCC patients (negative loadings) are labeled (A and B). 2HB indicates 2-hydroxybutyrate; 3HB, 3-hydroxybutyrate; Ac, acetone; Ace, acetate; AceAce, acetoacetate; ACL, acetyl-l-carnitine; Ala, alanine; Asn, asparagine; Bet, betaine; Car, carnitine; Cho, choline; Cit, citrate; Cr, creatine; Cre, creatinine; DMG, dimethylglycine; EtOH, ethanol; Gln, glutamine; Gluc, glucose; Gly, glycine; Lac, lactate; Lys, lysine; MeOH,methanol; Orn, ornithine; Pro, proline; Pyr, pyruvate; Sar, sarcosine; Ser, serine; Val, valine.
Figure 5
Figure 5
Schematic representation of the most relevant metabolic differences between oral cancer patients and healthy controls.
Figure 6
Figure 6
Loadings plots (latent variables) from a PLS-DA analysis of OSCC patients showing metabolites that discriminate between early (positive loadings) and late stage diseases (negative loadings). A representative NMR spectrum of human serum from an OSCC patient is shown above the loadings plots.
See this image and copyright information in PMC

References

    1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481–488. - PubMed
    1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592. - PubMed
    1. Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ, Genden E, Urken ML, Wang BY. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005;29:167–178. - PubMed
    1. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114:806–816. - PubMed
    1. Beckwith-Hall BM, Thompson NA, Nicholson JK, Lindon JC, Holmes E. A metabonomic investigation of hepatotoxicity using diffusion-edited H-1 NMR spectroscopy of blood serum. Analyst. 2003;128:814–818. - PubMed

Publication types

Substances

LinkOut - more resources